Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

VPA response in SMA is suppressed by the fatty acid translocase CD36

16 Oct 2012

Abstract excerpt

Functional loss of SMN1 causes proximal spinal muscular atrophy (SMA), the most common genetic condition accounting for infant lethality. Hence, the hypomorphic copy gene SMN2 is the only resource of functional SMN protein in SMA patients and influences SMA severity in a dose-dependent manner. Consequently, current therapeutic approaches focus on SMN2. Histone deacetylase inhibitors (HDACi), such as the short...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Family and Disability Support Research
Share to Genetics and Neurodevelopmental Disorders
Share to Neurogenetic and Muscular Disorders Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23077215
DOI: 10.1093/hmg/dds437

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VPA response in SMA is suppressed by the fatty acid translocase CD36PMID 23077215Read ↗

Spinal muscular atrophy and therapeutic prospects.Semantic proximity Read ↗

Spinal muscular atrophy: from gene to therapy.Semantic proximity Read ↗

Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophySemantic proximity Read ↗

VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse modelsSemantic proximity Read ↗

High Expression of SMN circ4-2b-3 in SMA I Children Treated with Nusinersen is Associated with Improved Motor OutcomesSemantic proximity Read ↗

Beyond SMN1 mutation: environmental predispositions and epigenetic contributors to phenotypic variability and disease severity in spinal muscular atrophy.Semantic proximity Read ↗

Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen.Semantic proximity Read ↗

A transcriptomics-based drug repositioning approach to identify drugs with similar activities for the treatment of muscle pathologies in spinal muscular atrophy (SMA) modelsSemantic proximity Read ↗

Targeted Antisense Oligonucleotide Treatment Rescues Developmental Alterations in Spinal Muscular Atrophy OrganoidsSemantic proximity Read ↗

A transcriptomics-based drug repositioning approach to identify drugs with similar activities for the treatment of muscle pathologies in spinal muscular atrophy (SMA) modelsSemantic proximity Read ↗

Combining multi-omics and drug perturbation profiles to identify novel treatments that improve disease phenotypes in spinal muscular atrophySemantic proximity Read ↗

Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.